Colony-forming unit cell of human chorion and method to obtain and use thereof

• US 8,771,677 B2
• Filed: 12/03/2009
• Issued: 07/08/2014
• Est. Priority Date: 12/29/2008
• Status: Active Grant

• Current Assignee: Frans A. Kuypers, Vladimir B. Serikov
• Original Assignee: Frans A. Kuypers, Vladimir B. Serikov
• Inventors: Kuypers, Frans A, Serikov, Vladimir B
• Primary Examiner(s): Weber, Jon P
• Assistant Examiner(s): GOUGH, TIFFANY MAUREEN
• Application Number:
  US12/591,857
• Publication Number:
  US 20100166716A1
• Time in Patent Office: 1,678 Days
• Field of Search: 424/93.7
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

The present invention features colony-forming unit cells derived from the chorion of human placenta and describes compositions and methods for the uses of chorionic cells and their products for therapeutic purposes based upon production and release of multiple growth factors and cytokines by these cells stimulating tissue regeneration independent of engraftment, as well as differentiation into a specific cell type.

Claims

1. Isolated colony-forming unit cells derived from the chorion of human term placentas, wherein the isolated colony-forming unit cells are multipotent stem cells characterized by:

I) expression of protein ACBD6;

II) low telomerase activity and ability to be propagated over at least 70 doublings in vitro culture without substantial alteration of karyotype;

III) expression of a combination of at least one of the markers from each of;

iv) CD-90, SSEA-3, or TRA-1-60;

v) a Nanog cytosolic polypeptide;

vi) a neurofilament family cytosolic polypeptide;

vii) a Nestin cytosolic polypeptide; and

viii) one or more secreted polypeptides selected from a family of fibroblast growth factors, hepatocyte growth factors, keratinocyte growth factors, and angiopoietins; and

ix) nuclear peptide Oct-4;

IV) lack the ability for spontaneous differentiation into lineages of 3 germ layers under standard culture conditions, unless specifically stimulated and lack the ability for formation of teratomas in humans or immuno-compromised animals;

V) ability to differentiate into lineages of all 3 germ layers when the cells are exposed to lineage-specific differentiation conditions;

VI) ability to grow without adherence to plastic; and

VII) inability to form embryoid-like bodies.

2. The isolated colony-forming unit cells of claim 1, wherein the cells are capable of repopulating organs of humans or immunodeficient animals without formation of teratomas.

3. A pharmaceutical composition comprising isolated colony-forming unit cells of claim 1 and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising isolated colony-forming unit cells of claim 1, an effective amount of any other cell population, and a pharmaceutically acceptable carrier.

5. A tissue-engineered construct, comprising isolated colony-forming unit cells of claim 1 and a biocompatible polymer scaffold.

6. A method of enhancing regeneration of diseased tissue of organs, comprising administering to the diseased tissue the cells of claim 1 by local or systemic delivery of said cells.

7. A method of claim 6 where the organ is heart.

8. A method of claim 6 where the organ in spinal cord.

9. A method of claim 6 where the organ is striated muscle.

10. A method of claim 6 where the organ is peripheral nerve.